Actively Recruiting
Randomized Clinical Trial of Intranasal Injection of Platelet-Rich Plasma for Treatment of Parosmia
Led by Stanford University · Updated on 2024-11-22
40
Participants Needed
1
Research Sites
121 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This randomized clinical trial will evaluate the benefit of platelet-rich plasma (PRP) in the treatment of qualitative olfactory dysfunction (parosmia). PRP can be isolated from a patient's own blood and has been found in previous studies to have anti-inflammatory and pro-regenerative properties. It has been used across multiple specialties, such as Orthopedics, Facial Plastics, Dermatology, Neurology in injected form to treat a wide variety of tissues to encourage the body's inherent regenerative capacity. The investigators have completed a randomized controlled trial here, ending in 2022, evaluating it's use in post-SARS-CoV-2 olfactory loss which demonstrated safety and efficacy. Therefore, the investigators aim to assess the ability of PRP to improve olfactory function in patients with parosmia.
CONDITIONS
Official Title
Randomized Clinical Trial of Intranasal Injection of Platelet-Rich Plasma for Treatment of Parosmia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients 18 years of age or older
- Qualitative olfactory distortion (parosmia)
- Olfactory distortion caused by an upper respiratory infection
- Score below the 10th percentile on the Sniffin Sticks Parosmia Test
- Score of 8 or higher on the questionnaire of olfactory disorders
- Parosmia symptoms lasting at least 6 months but less than 24 months
- May have been previously treated with oral or topical steroids (not required)
- Will receive concurrent olfactory training
- Able to read and understand English
- Able and willing to provide informed consent
You will not qualify if you...
- Patients under 18 years of age
- Pregnant females
- Structural abnormalities in the nose preventing injection
- Olfactory loss due to trauma, chronic sinusitis, inflammation, polyps, neoplasms, or neurodegenerative diseases
- Olfactory loss lasting more than 24 months
- Patients with bleeding disorders or taking blood thinners such as coumadin or plavix
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Stanford Sinus Center / Stanford University School of Medicine
Palo Alto, California, United States, 94304
Actively Recruiting
Research Team
H
Homer Abaya, BS
CONTACT
M
Maxime Fieux, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here